Huma Therapeutics has raised $130 million to fund its digital health platform.

The money will be spent on scaling the British healthcare company’s modular platform, which can power digital ‘hospitals at home’ nationally by supporting pharmaceutical and research industries to run what it describes as “the largest ever decentralised clinical trials.”

The funding will also be used to expand Huma’s digital platform in the US, Asia, and the Middle East.

Huma currently has existing partnerships with the NHS and national governments in Germany and the United Arab Emirates.

The company has already started to advance its work in the US this year.

Huma’s platform combines predictive algorithms, digital biomarkers, and real-world data.

The investment arms of leading health and tech companies, including Bayer, Hitachi, Samsung, Sony Innovation Fund by IGV, Unilever and the PE fund HAT, were all involved in the funding round.

“This is a pivotal moment in Huma’s development. We have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives,” said Dan Vahdat, founder and chief executive, Huma. “We’re already demonstrating how ‘hospital at home’ can transform healthcare, and how decentralised clinical trials can advance research in ways that weren’t imaginable even one year ago. Now we want to accelerate the pace of change and continue to innovate for better care and research worldwide.’’

Alan Milburn, former UK health secretary and chairman of Huma’s board, said, “This is a significant moment in Huma’s history and I will work to build enduring, trusted relationships with our new partners. We are living through unprecedented times and the importance of health and well-being is underlined as never before. Together with our partners we can use our expertise, technology, and innovation to change the face of healthcare and research and impact people’s health everywhere.”

Share Story: